Tevimbra

Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

HARMONi-6 marks the first phase 3 trial in which a regimen has beaten the combination of a PD-1 inhibitor and chemotherapy on PFS in first-line NSCLC.

Angus Liuu Oct 19, 2025 10:45am

FDA limits Keytruda, Opdivo uses in stomach cancer

Jun 9, 2025 10:50am

Akeso's fast-rising ivonescimab scores 3rd lung cancer trial win

Apr 23, 2025 11:30am

AstraZeneca-CSPC, Astellas and more—Fierce Pharma Asia

Oct 11, 2024 9:48am

BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda

Oct 4, 2024 10:37am

Experts back FDA's plan to restrict PD-1 drugs in GI cancers

Sep 26, 2024 1:38pm